➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Baxter
Mallinckrodt
AstraZeneca
McKesson

Last Updated: May 28, 2020

DrugPatentWatch Database Preview

FUNDUSCEIN-25 Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Funduscein-25, and what generic alternatives are available?

Funduscein-25 is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in FUNDUSCEIN-25 is fluorescein sodium. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the fluorescein sodium profile page.

Summary for FUNDUSCEIN-25
Drug patent expirations by year for FUNDUSCEIN-25
Synonyms for FUNDUSCEIN-25
(3H)Xanthen-3-one, 10-deshydro-6-hydroxy-10-[2-carboxyphen-1-yl]-
1flr
1n0s
2-(3-hydroxy-6-keto-xanthen-9-yl)benzoic acid
2-(3-hydroxy-6-oxo-6H-xanthen-9-yl)benzoic acid
2-(6-HYDROXY-3-OXO-3H-XANTHEN-9-YL)-BENZOIC ACID
2-(6-Hydroxy-3-oxo-3H-xanthen-9-yl)benzoesaure
2-(6-Hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid
2-(6-Hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid #
2-(6-hydroxy-3-oxoxanthen-9-yl)benzoic acid
2-(6-oxido-3-oxo-3H-xanthen-9-yl)benzoate
3',6'-Dihydroxy-spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one
3'',6''-dihydroxyspiro[1,3-dihydroisobenzofuran-1,9''-(9''H-xanthene)]-3-one
321H075
3H-Xanthen-3-one, 6-hydroxy-10-[2-carboxyphenyl]-
518-45-6
AKOS000503167
ARONIS014456
BBL002034
BDBM50143424
C.I.45350:1
CBDivE_002901
CHEMBL177756
CI 45350
cid_3383
CTK1G3923
flourescein
Fluorescite
KS-000044VW
MCULE-8810198732
NS-05493
Q27460338
SBB001359
SCHEMBL107875
ST009474
STK391288
T7547
TG2-210
YKGGGCXBWXHKIZ-UHFFFAOYSA-N
ZINC3872582

US Patents and Regulatory Information for FUNDUSCEIN-25

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis FUNDUSCEIN-25 fluorescein sodium INJECTABLE;INJECTION 017869-001 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Baxter
Mallinckrodt
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.